Last updated: February 22, 2026
What is the Drug and Its Market Position?
NDC 16714-0643 corresponds to Leqvio (inclisiran), an intravenous lipid-lowering agent used to reduce LDL cholesterol in adults with familial hypercholesterolemia or established atherosclerotic cardiovascular disease. Approved by the FDA in December 2020, Leqvio is marketed by Novartis.
Inclisiran functions as a small interfering RNA (siRNA) that inhibits PCSK9 production, leading to reduced LDL cholesterol levels. Its dosing schedule—initial dose, at three months, then every six months—positions it as a twice-yearly alternative to statins and PCSK9 monoclonal antibodies (mAbs).
Market Overview
Diagnosed Population & Prescriptions
- Target Population: Estimated 15 million Americans with familial hypercholesterolemia or high ASCVD risk.
- Market Penetration: As of 2023, approximately 20,000 patients have initiated inclisiran therapy in the US.
- Comparative market share: PCSK9 mAbs (e.g., Repatha, Praluent) hold a dominant 80% market share among lipid-lowering injectables. Inclisiran captures approximately 7%, with room for growth.
Competitive Landscape
| Drug |
Type |
Dosing Frequency |
Annual Cost (2023 USD) |
Market Share (2023) |
| Repatha (evolocumab) |
Monoclonal antibody |
Weekly or monthly |
$6,600 |
55% |
| Praluent (alirocumab) |
Monoclonal antibody |
Biweekly or monthly |
$6,400 |
25% |
| Inclisiran (Leqvio) |
siRNA-based |
Every six months |
$3,850 (list) |
7% |
Source: IQVIA, Novartis pricing (2023)
Clinical Advantages
- Twice-yearly dosing improves adherence.
- Similar LDL reduction efficacy compared to PCSK9 mAbs.
- Potential to expand use into broader lipid management populations.
Price Trends and Cost Projections
Current Pricing
Inclisiran's base wholesale acquisition cost (WAC) is approximately $3,850 per dose, totaling about $7,700 annually for two doses. negotiated net prices are typically 20-30% lower.
Market Expansion Scenarios
- Conservative Scenario: 10% annual growth in prescriptions over 5 years, reaching 100,000 patients.
- Aggressive Scenario: 25% annual growth, accelerated adoption in primary care, reaching 250,000 patients.
Price Impact Factors
- Insurance Reimbursement Policies: Medicare and private insurers may negotiate discounts.
- Generics & Biosimilars: Not applicable due to mechanism of action and molecular complexity.
- Market Competition: Entry of new siRNA therapies or biosimilars could reduce prices.
Price Projections (2024-2028)
| Year |
Projected Patients (conservative) |
Revenue (USD millions) |
Average Price per Dose (USD) |
| 2024 |
50,000 |
385 |
$3,850 |
| 2025 |
75,000 |
578 |
$3,850 |
| 2026 |
100,000 |
770 |
$3,850 |
| 2027 |
150,000 |
1,155 |
$3,850 |
| 2028 |
250,000 |
1,925 |
$3,850 |
Under aggressive assumptions, revenue could exceed USD 2 billion annually by 2028.
Key Market Drivers & Limiters
Drivers
- Rising prevalence of hyperlipidemia.
- Increasing awareness of cardiovascular risk management.
- Patient preference for less frequent injections.
- Expanded clinical indications and guidelines.
Limiters
- High current cost relative to traditional statins.
- Reimbursement restrictions.
- Slow uptake in primary care settings.
- Limited long-term real-world data.
Summary
Inclisiran is positioned as a niche but growing player within lipid-lowering therapies. Its success depends on expanding market share, refinancing pricing negotiations, and clinician awareness. Price projections suggest potential revenues approaching USD 2 billion annually by 2028 if adoption trends accelerate.
Key Takeaways
- NDC 16714-0643 (Leqvio) has an initial list price of approximately USD 3,850 per dose.
- Market share remains small but is expected to grow with expanding indications and increased physician adoption.
- Revenue projections over five years can reach USD 2 billion annually under optimistic adoption scenarios.
- Cost containment strategies like negotiated rebates and formulary positioning remain critical for growth.
- Competition from existing PCSK9 antibodies and future BIologics will influence pricing dynamics.
FAQs
1. How does inclisiran's pricing compare to PCSK9 inhibitors?
Inclisiran's list price of about USD 3,850 per dose is roughly 40-50% lower than monoclonal antibody therapies, which cost about USD 6,400 to USD 6,600 annually.
2. What factors influence the future price of inclisiran?
Reimbursement negotiations, competition, regulatory decisions, and market penetration will determine the net price over time.
3. Will expanding indications impact the drug's price?
Broader indications could increase demand, enabling pricing adjustments, but payers may seek discounts to accommodate larger patient populations.
4. How does treatment adherence affect market potential?
Less frequent dosing could improve adherence, increasing overall use and driving revenue growth.
5. What regulatory developments could influence market outlook?
FDA approval for additional indications or inclusion in broader clinical guidelines could accelerate uptake, impacting pricing and revenue projections.
References
[1] IQVIA. (2023). Market Trends in Lipid-Lowering Therapies.
[2] Novartis. (2023). Leqvio Product Information.
[3] U.S. Food and Drug Administration. (2020). FDA approves Inclisiran for treatment of high LDL cholesterol.
